drugset / Trial / NCT00115544
Safety and Pharmacology of Stanate
Phase 2
Completed
55 enrolled
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
National Children's Hospital, Vietnam · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the effect and safety of Stanate (stannsoporfin) in infants who are at risk for an exchange transfusion and meet the criteria of the protocol.
Timeline
- Start
- 2005-09
- Primary completion
- 2006-07
- Completion
- 2006-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | stannsoporfin | Small molecule | 0.75 mg/kg | Intramuscular |
| Subject | stannsoporfin | Small molecule | 1.5 mg/kg | Intramuscular |